Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)
Recruiting · NCT06796998 · Registry updated 2025-10-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, MALT lymphoma, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, marginal zone lymphoma, neoplasm, nodal marginal zone B-cell lymphoma, splenic marginal zone lymphoma | Recruiting | Phase 2 | 2025-10-28 | NCT06796998 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AbbVie | 340 |
| Genmab | 54 |
| Izidore Lossos, MD | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Miami | Miami | United States | 327 |